HER2-low breast cancer
Oncology · 2023–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| trastuzumab deruxtecan Treatment of patients with HER2-low (IHC 1+ or IHC 2+/ISH negative) unresectable or metastatic breast cancer who have received prior chemotherapy in the… | Mar 2024 | Recommended with restriction | input received Breast Cancer Network · Medical Oncology Group |
| trastuzumab deruxtecan Treatment of patients with HER2 low (IHC 1+ or IHC 2+/ISH negative) unresectable or metastatic breast cancer who have received prior chemotherapy in the… | Nov 2023 | Not recommended | 2 individuals Breast Cancer Network Australia · Breast Cancer Special Interest Group · Rare Cancers Australia · Medical Oncology Group |
Who spoke
Medical Oncology Group · Breast Cancer Network · Breast Cancer Network Australia · Breast Cancer Special Interest Group · Rare Cancers Australia
What the PBS pays
$99M in government benefit over 2024–25, across 9,999 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| trastuzumab deruxtecan | $98.9M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 0 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| trastuzumab deruxtecanTrastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy | TA992 | not recommended | 2024-07 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.